Ichnos Glenmark Innovation (IGI), an alliance between Glenmark Pharma (BOM:532296, NSE:GLENMARK) and its wholly owned subsidiary Ichnos Glenmark Innovation, shared promising Phase 1 data for ISB 2001, a first-in-class trispecific antibody for relapsed/refractory multiple myeloma.
The TRIgnite-1 study showed a 74% overall response rate in heavily pretreated patients, with an 84% response in those without prior CAR-T or bispecific therapies.
ISB 2001 targets BCMA, CD38, and CD3 to boost immune attack on myeloma cells, showing deep, durable responses and a manageable safety profile. The US FDA granted it Fast Track status in May.
The study is moving to dose expansion to refine dosing and further evaluate effectiveness.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.